Staar Surgical price target lowered to $67 from $80 at BTIG

BTIG analyst Ryan Zimmerman lowered the firm’s price target on Staar Surgical to $67 from $80 and keeps a Buy rating on the shares. The company’s announced CEO change was "abrupt" and with little clarity on why it happened, the analyst tells investors in a research note. Zimmerman adds that if new CEO Tom Frinzi had been involved in Staar’s 3-year strategic plan as indicated, he would have been comfortable with reiterating the company FY23 guidance, which the management omitted. The analyst further notes that the next step is likely a reset of FY23 guidance.